• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Nano Dimension Board Sets the Record Straight on Murchinson's Self-Interested and Destructive Campaign

    7/9/26 6:45:00 PM ET
    $NNDM
    Electrical Products
    Technology
    Get the next $NNDM alert in real time by email

    If Murchinson Wins, They Would Control 100% of The Board

    The Upcoming Extraordinary General Meeting Is Not A Vote On Any Strategic Transaction

    Nano Dimension Ltd. (NASDAQ:NNDM) ("Nano Dimension," "Nano," or the "Company") today issued the following letter to shareholders regarding its upcoming Extraordinary General Meeting ("EGM") scheduled for July 31, 2026. Nano's Board of Directors (the "Board") urges shareholders to carefully evaluate its recommendations and vote accordingly.

    Dear Fellow Shareholders:

    The upcoming Extraordinary General Meeting centers on a fundamental question: should Murchinson Ltd. and certain of its affiliates ("Murchinson") be empowered to take control of your Company by replacing the independent directors with their own hand-picked loyalists?

    To address this, it is important to understand the origins of the current dispute.

    This proxy contest arose out of Murchinson's persistent, inappropriate demands of the Company to advance its individual self-interest to the detriment of the Company's other shareholders and the Board's rejection of Murchinson's improper demands consistent with the Board’s fiduciary duty to all shareholders.

    Murchinson is seeking to replace three of the Company’s five directors. Notably, two of those directors were originally nominated by Murchinson. In addition, a third director who Murchinson is not seeking to remove, was also nominated by Murchinson and remains aligned with its interests. Further, Andy Sriubas, a current independent director, has publicly disclosed that he will not continue to serve on the Board if Murchinson gains control. As a result, if Murchinson’s proposals are approved, it would control 100% of the Board through its newly appointed directors together with the director who remains aligned with and loyal to Murchinson.

    Several examples of Murchinson's inappropriate, self-interested conduct and the Board's response follow. Please note these examples are an illustrative subset of Murchinson's extensive and persistent improper conduct, and the Board's determination to protect the interests of all of the Company's shareholders.

    Examples of Murchinson’s Demands and the Board’s Independent Responses

    Murchinson Demand

    Board Response

    Demanded that the Company reimburse Murchinson $15 million for prior activism campaigns and litigation costs.

    Rejected.

     

    Murchinson did not provide supporting documentation or detailed expense information to substantiate its requested reimbursement of $15 million.

    Demanded the Company engage Murchinson as its litigation advisor pursuant to a litigation trust with significant fees payable to Murchinson.

    Rejected.

     

    The Board concluded that Murchinson's proposed arrangements would create significant conflicts of interest and would result in a transfer of value from the Company to Murchinson that would be inconsistent with the Board's fiduciary duties to all shareholders.

    Demanded members of the Board, and specifically those directors nominated by Murchinson, take direction from Murchinson on corporate and strategic matters.

    Rejected.

     

    The Board believes that taking such actions would be inconsistent with each director's obligation to act independently and in the best interests of all of the Company's shareholders.

    Demanded the Board appoint Marc Bistricer to the Board while insisting Murchinson would not agree to normal and customary provisions of a settlement agreement.

    In April 2026 the Board attempted to negotiate a settlement agreement with Murchinson, but Murchinson rejected all reasonable proposals of the Company.

    Shareholders should also be aware that Murchinson has been subject to prior regulatory action, including an SEC Administrative Proceeding in 2021 resulting in an approximately $8 million fine. The Board believes Murchinson’s inappropriate and improper demands of the Company are consistent with Murchinson's misconduct in other circumstances that has resulted in regulatory action against it.

    We would like to emphasize that the upcoming Extraordinary General Meeting is about determining whether the existing Board or Murchinson's new hand-picked replacements, who would constitute 100% of the Board, are best equipped to represent the interests of all Company shareholders, and when necessary, take a stand against further inappropriate, self-interested and/or value destructive demands coming from Murchinson. It is not a referendum on the Company's past or the Company's current strategic plans. Nevertheless, we would like to put some issues of the past as well as current strategic initiatives in context.

    All current members of the Board joined during or after December 2024. Prior to that, the prior Board made several irreversible decisions that the current Board inherited. This included definitive agreements to acquire Desktop Metal, Inc. and Markforged Holding Corporation. These agreements were hastily negotiated by prior management, approved by the prior Board and committed the Company to consummate them without giving the Company's shareholders the opportunity or right to vote on them. The current Board has been addressing the consequences of the prior Board's decisions.

    By contrast, the current Board conducted a thorough review of all strategic alternatives available to the Company with the assistance of Houlihan Lokey and Guggenheim Securities, LLC, and identified the potential Infinite Epigenetics transaction as the best prospect for maximizing shareholder value. The Board understands that based on the information the Company has provided so far, many shareholders have mixed feelings about the proposed transaction with Infinite Epigenetics. If the Board approves a definitive merger agreement with Infinite Epigenetics, the Board intends to provide more extensive information regarding this opportunity and why the Board believes it has the prospect for generating significant long-term shareholder value for the Company and its shareholders.

    The upcoming Extraordinary General Meeting is not a vote on any strategic transaction. Rather, it is a vote on whether shareholders believe the current Board should continue to exercise independent judgment, oversee the Company, and continue a structured review of strategic alternatives in the best interests of all shareholders.

    The Board believes this structure preserves full shareholder choice while ensuring a disciplined and transparent process at every stage. Simply put, if the Board approves the Company’s execution of a definitive agreement with Infinite Epigenetics, shareholders will have the opportunity to vote at a later meeting on whether to approve that transaction.

    In addition, since the announcement of the proposed Infinite Epigenetics transaction, the Company has received an unsolicited, publicly disclosed all cash merger proposal from Tang Capital. The Board believes any potential strategic alternative should be addressed through a disciplined process consistent with its fiduciary duties and applicable law. Shareholders deserve sufficient information and adequate time to evaluate any transaction requiring shareholder approval before being asked to vote.

    The Board strongly recommends that at the upcoming Extraordinary General Meeting shareholders vote in accordance with the Board’s recommendations set forth below and in the Company’s proxy materials.

    VOTE THE WHITE PROXY CARD AS FOLLOWS

    Proposal

    Description

    Board Recommendation

    Proposal 1

    To approve on a non-binding advisory basis a resolution regarding the continuation of the Company's strategic alternatives review process including any related transaction approved by the Board

    FOR

    Proposal 2

    To approve the Proposing Shareholders' proposal to amend Article 39 of the Articles

    FOR

    Proposal 3

    To approve the Proposing Shareholders' proposal to add a new Article 71 to the Articles

    AGAINST

    Proposal 4

    To approve the Proposing Shareholders' proposal to add a new Article 72 to the Articles

    AGAINST

     

    To approve the Proposing Shareholders' proposal to dismiss the following three (3) of the Company's directors from office and to dismiss any new directors appointed after May 21, 2026 ("Proposal No. 5"):

     

     

     

    5a. Robert Pons

    AGAINST

    Proposal 5

     

     

    5b. Joshua Rosensweig

    AGAINST

     

     

    5c. David Stehlin

    AGAINST

     

     

    5d. Any and all new directors appointed by the Board of Directors of the Company on or following May 21, 2026

    AGAINST

     

    Subject to the approval of Proposal No. 5, to approve the Proposing Shareholders' proposal to elect the following three (3) new directors in three (3) of the resulting vacancies:

     

     

     

    Proposal 6

    6a. Moshe Rozenbaum

    AGAINST

     

     

    6b. Eliezer Eli Tarlow

    AGAINST

     

     

    6c. Paul Fruchthandler

    AGAINST

     
     

    Expected timeline:

    • June 25, 2026: The Company filed its definitive proxy statement for the upcoming Extraordinary General Meeting.
    • July 31, 2026: Extraordinary General Meeting.
    • Fall 2026: If a definitive agreement is reached regarding the Infinite Epigenetics transaction, shareholders are expected to receive additional information and have the opportunity to vote on the binding transaction.

    How to vote:

    Shareholders should follow the instructions on their WHITE proxy card, voting instruction form or materials received from their broker, bank, or other nominee.

    Questions or need assistance voting:

    If you have any questions or need assistance in voting your shares, please contact our proxy solicitor:

    Innisfree M&A Incorporated

    Shareholders may call 1 (877) 750-9498 (toll-free from the U.S. and Canada) or +1 (412) 232-3651 (from other countries).

    Banks and Brokers may call collect: (212) 750-5833

    About Nano Dimension Ltd.

    Nano Dimension Ltd. (NASDAQ:NNDM) has historically delivered advanced digital manufacturing technologies serving customers across the defense, aerospace, automotive, electronics and medical device industry segments. Following a strategic review process initiated in 2025, the Company has focused on streamlining its operations, reducing cash burn, monetizing product lines and evaluating opportunities to deploy its capital base and publicly traded company platform into a more compelling long-term value creation opportunity. Nano Dimension continues to operate its remaining product lines, while the Company advances its strategic plan and evaluates the proposed business combination with Infinite Epigenetics. For more information, please visit www.nano-di.com.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding the extraordinary general meeting requisitioned by Murchinson, Nano Dimension’s strategic plan, the view of Nano Dimension’s Board on the reasonableness and appropriateness of the actions taken and not taken by Murchinson, and all other statements other than statements of historical fact that address activities, events or developments that Nano Dimension intends, expects, projects, believes or anticipates will or may occur in the future. Forward-looking statements may be characterized by terminology such as "believe," "project," "expect," "anticipate," "estimate," "forecast," "outlook," "target," "endeavor," "seek," "predict," "intend," "strategy," "plan," "may," "could," "should," "will," "would," "continue," "likely," or the negative thereof or variations thereon or similar terminology generally intended to identify forward-looking statements. Such statements are based on management’s beliefs and assumptions made based on information currently available to management. These forward-looking statements involve known and unknown risks and uncertainties, which may cause the Company’s actual results and performance to be materially different from those expressed or implied in the forward-looking statements. Accordingly, the Company cautions shareholders that any such forward-looking statements are not guarantees of future performance and are subject to risks, assumptions, estimates and uncertainties that are difficult to predict. The forward-looking statements contained or implied in this communication are subject to other risks and uncertainties, including, but not limited to those discussed under the heading "Risk Factors" in Nano Dimension’s annual report on Form 10-K for the fiscal year ended December 31, 2025, filed with the U.S. Securities and Exchange Commission (the "SEC") on March 31, 2026, and in any subsequent filings with the SEC.

    Except as otherwise required by law, Nano Dimension undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this communication.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20260709320922/en/

    Investors:

    Purva Sanariya

    Director, Investor Relations

    ir@nano-di.com

    Media:

    Samuel Manning

    Principal Manager, External Communications

    press@nano-di.com

    Get the next $NNDM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NNDM

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NNDM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Stehlin David covered exercise/tax liability with 24,971 units of Ordinary Shares, decreasing direct ownership by 3% to 737,032 units (SEC Form 4) to satisfy withholding obligation

    4 - Nano Dimension Ltd. (0001643303) (Issuer)

    7/14/26 4:15:13 PM ET
    $NNDM
    Electrical Products
    Technology

    Chief Executive Officer Stehlin David covered exercise/tax liability with 19,841 units of Ordinary Shares, decreasing direct ownership by 3% to 762,003 units (SEC Form 4) to satisfy tax liability

    4 - Nano Dimension Ltd. (0001643303) (Issuer)

    6/10/26 4:15:18 PM ET
    $NNDM
    Electrical Products
    Technology

    Director Sriubas Andrew was granted 160,000 units of Ordinary Shares, increasing direct ownership by 400% to 200,015 units (SEC Form 4)

    4 - Nano Dimension Ltd. (0001643303) (Issuer)

    6/4/26 4:01:49 PM ET
    $NNDM
    Electrical Products
    Technology

    $NNDM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Nano Dimension Announces Appointment of Interim Chief Executive Officer and Chairman of the Board

    WALTHAM, Mass., July 21, 2026 (GLOBE NEWSWIRE) -- Nano Dimension Ltd. (NASDAQ:NNDM) ("Nano Dimension," "Nano", or the "Company") today announced the appointment of Moshe Rozenbaum as Interim Chief Executive Officer ("CEO"), effective immediately. The Company’s Board of Directors (the "Board") has also appointed Phillip Borenstein as Chairman of the Board. Mr. Rozenbaum will work closely with the Board and the Company’s leadership to support business continuity while the Board evaluates the Company’s strategic priorities and opportunities moving forward. Phillip Borenstein, Chairman of the Board, commented, "On behalf of myself and the entire Board of Directors, we are pleased to appoint

    7/21/26 4:05:00 PM ET
    $NNDM
    $LFWD
    Electrical Products
    Technology
    Industrial Specialties
    Health Care

    Nano Dimension and Murchinson Announce Agreement to Reconstitute the Company’s Board of Directors

    WALTHAM, Mass., July 20, 2026 (GLOBE NEWSWIRE) -- In connection with the upcoming July 31, 2026, Extraordinary General Meeting of Shareholders (the "July EGM"), Nano Dimension Ltd. (NASDAQ:NNDM) ("Nano Dimension," "Nano," or the "Company") and Murchinson Ltd. (collectively with its affiliates and funds it advises and/or sub-advises, "Murchinson") today jointly announced a settlement agreement. Under the terms of the agreement executed on July 17, the July EGM will be cancelled. Messrs. Pons, Rosensweig, Sriubas and Stehlin (collectively, the "Departing Directors") resigned from the Board and all their positions at Nano. The directors nominated by Murchinson for the July EGM — Messrs. Fruc

    7/20/26 8:30:00 AM ET
    $NNDM
    Electrical Products
    Technology

    QTREX Appoints Dr. Shlomit Chappel-Ram, Veteran AME R&D Executive, as Independent Director

    Ness Ziona, Israel, July 17, 2026 (GLOBE NEWSWIRE) -- QTREX Quantum Ltd. (NASDAQ:QTEX) ("QTREX" or the "Company"), a company focused on advancing Additively Manufactured Electronics ("AME") for quantum computing infrastructure, today announced that on July 14, 2026, its Board of Directors (the "Board") appointed Dr. Shlomit Chappel-Ram as an independent director, effective immediately. Dr. Chappel-Ram previously served as Vice President of R&D at Nano Dimension Ltd. (NASDAQ:NNDM), where she led multidisciplinary teams spanning materials, formulations, chemistry, physics, process engineering, mechanics, software, hardware, and electronics. She also co-authored peer-reviewed IEEE research o

    7/17/26 8:30:00 AM ET
    $IINN
    $NNDM
    Medical/Dental Instruments
    Health Care
    Electrical Products
    Technology

    $NNDM
    SEC Filings

    View All

    SEC Form 8-K filed by Nano Dimension Ltd.

    8-K - Nano Dimension Ltd. (0001643303) (Filer)

    7/21/26 4:05:15 PM ET
    $NNDM
    Electrical Products
    Technology

    SEC Form 144 filed by Nano Dimension Ltd.

    144 - Nano Dimension Ltd. (0001643303) (Subject)

    7/14/26 7:54:34 AM ET
    $NNDM
    Electrical Products
    Technology

    SEC Form DEFA14A filed by Nano Dimension Ltd.

    DEFA14A - Nano Dimension Ltd. (0001643303) (Filer)

    7/10/26 9:15:18 AM ET
    $NNDM
    Electrical Products
    Technology

    $NNDM
    Financials

    Live finance-specific insights

    View All

    Murchinson Criticizes the Nano Dimension Board of Directors' Decision to Pursue a Seemingly Deeply Flawed Transaction with Infinite Epigenetics

    Believes the Proposed Transaction Represents a Misallocation of Corporate Resources That Would Significantly Dilute Existing Shareholders Finds It Deeply Concerning That This Morning's Conference Call Offered Shareholders Little Beyond Buzzwords and Provided No Opportunity to Ask Questions Regarding a Transaction That Materially Impacts the Future of the Company Murchinson Ltd. (collectively with its affiliates and funds it advises and/or sub-advises, "Murchinson" or "we"), a significant shareholder with approximately 7.4% of the outstanding shares of Nano Dimension Ltd. (NASDAQ:NNDM) ("Nano" or the "Company"), today commented on Nano's announcement that it has signed a non-binding term

    6/15/26 5:55:00 PM ET
    $NNDM
    Electrical Products
    Technology

    Nano Dimension Signs Term Sheet with Infinite Epigenetics to Form a Publicly Traded, AI-Powered Preventive Health and Diagnostics Company

    Nano Dimension Conducted a Rigorous Multi-Month Strategic Review, Assessing Approximately 20 Companies Before Selecting Infinite Epigenetics as the Most Compelling Path to Long-Term Value CreationProposed Combination Would Deploy Nano Dimension's Capital Base and Nasdaq listing into a High-Growth Healthcare AI OpportunityExisting Nano Shareholders Expected to Retain Meaningful Minority Ownership in Combined Company on a Stated Value for Nano Dimension's Shares that Reflects a 20% Premium to Nano Dimension's Estimated Net Cash at ClosingInfinite Epigenetics Transaction Value of $890 million Infinite Epigenetics Targets a $90B+ U.S. Clinical Diagnostics Market Opportunity Across its Core Disea

    6/15/26 7:27:56 AM ET
    $NNDM
    Electrical Products
    Technology

    Murchinson Invites Fellow Nano Dimension Shareholders to an Investor Call to Discuss the Current State of the Company

    It Is Time to Talk About Nano Dimension Murchinson Ltd. (collectively with its affiliates and funds it advises and/or sub-advises, "Murchinson" or "we"), a significant shareholder with approximately 7.4% of the outstanding shares of Nano Dimension Ltd. (NASDAQ:NNDM) ("Nano" or the "Company"), today announced it will host an investor conference call to discuss the Company's so-called strategic review, Chairman Bob Pons' role in the "review process," and other concerns related to the Company's business and corporate governance. After eight months of limited progress and minimal communication from Nano regarding its strategic review, Murchinson believes shareholders deserve a constructive

    5/26/26 5:00:00 PM ET
    $NNDM
    Electrical Products
    Technology

    $NNDM
    Leadership Updates

    Live Leadership Updates

    View All

    Nano Dimension Announces Appointment of Interim Chief Executive Officer and Chairman of the Board

    WALTHAM, Mass., July 21, 2026 (GLOBE NEWSWIRE) -- Nano Dimension Ltd. (NASDAQ:NNDM) ("Nano Dimension," "Nano", or the "Company") today announced the appointment of Moshe Rozenbaum as Interim Chief Executive Officer ("CEO"), effective immediately. The Company’s Board of Directors (the "Board") has also appointed Phillip Borenstein as Chairman of the Board. Mr. Rozenbaum will work closely with the Board and the Company’s leadership to support business continuity while the Board evaluates the Company’s strategic priorities and opportunities moving forward. Phillip Borenstein, Chairman of the Board, commented, "On behalf of myself and the entire Board of Directors, we are pleased to appoint

    7/21/26 4:05:00 PM ET
    $NNDM
    $LFWD
    Electrical Products
    Technology
    Industrial Specialties
    Health Care

    QTREX Appoints Dr. Shlomit Chappel-Ram, Veteran AME R&D Executive, as Independent Director

    Ness Ziona, Israel, July 17, 2026 (GLOBE NEWSWIRE) -- QTREX Quantum Ltd. (NASDAQ:QTEX) ("QTREX" or the "Company"), a company focused on advancing Additively Manufactured Electronics ("AME") for quantum computing infrastructure, today announced that on July 14, 2026, its Board of Directors (the "Board") appointed Dr. Shlomit Chappel-Ram as an independent director, effective immediately. Dr. Chappel-Ram previously served as Vice President of R&D at Nano Dimension Ltd. (NASDAQ:NNDM), where she led multidisciplinary teams spanning materials, formulations, chemistry, physics, process engineering, mechanics, software, hardware, and electronics. She also co-authored peer-reviewed IEEE research o

    7/17/26 8:30:00 AM ET
    $IINN
    $NNDM
    Medical/Dental Instruments
    Health Care
    Electrical Products
    Technology

    Nano Dimension and Infinite Epigenetics Provide Additional Information Regarding Proposed Business Combination

    WALTHAM, Mass., June 16, 2026 (GLOBE NEWSWIRE) -- Nano Dimension Ltd. (NASDAQ:NNDM) ("Nano Dimension," "Nano", or the "Company") and Infinite Epigenetics™ ("Infinite Epigenetics," "Infinite") today issued the following shareholder update to provide additional detail on the proposed business combination announced on June 15, 2026. The Company has carefully reviewed Murchinson's recent letter regarding the proposed transaction with Infinite. While we welcome shareholder engagement and are committed to transparency, the final details of the transaction are still being negotiated. However, we would like to address specific questions posed by Murchinson, contextualize the Infinite story and com

    6/16/26 7:43:26 PM ET
    $NNDM
    Electrical Products
    Technology

    $NNDM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Nano Dimension Ltd.

    SC 13D/A - Nano Dimension Ltd. (0001643303) (Subject)

    11/13/24 11:31:24 AM ET
    $NNDM
    Electrical Products
    Technology

    Amendment: SEC Form SC 13D/A filed by Nano Dimension Ltd.

    SC 13D/A - Nano Dimension Ltd. (0001643303) (Subject)

    10/23/24 8:21:43 PM ET
    $NNDM
    Electrical Products
    Technology

    Amendment: SEC Form SC 13D/A filed by Nano Dimension Ltd.

    SC 13D/A - Nano Dimension Ltd. (0001643303) (Subject)

    10/11/24 4:47:45 PM ET
    $NNDM
    Electrical Products
    Technology